Thomas Eissing
Overview
Explore the profile of Thomas Eissing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitt W, Diedrich C, Hamza T, Meyer M, Eissing T, Breitenstein S, et al.
Pediatr Cardiol
. 2024 May;
46(3):694-703.
PMID: 38722325
Plasma N-terminal prohormone B-type natriuretic peptide (NT-proBNP) concentration is a heart failure (HF) biomarker in adults and children. Its prognostic value for HF-related events has been established only in adults....
2.
Stahl A, Azuma N, Wu W, Lepore D, Sukgen E, Nakanishi H, et al.
Eye (Lond)
. 2024 Feb;
38(8):1599-1600.
PMID: 38332376
No abstract available.
3.
Stahl A, Azuma N, Wu W, Lepore D, Sukgen E, Nakanishi H, et al.
Eye (Lond)
. 2024 Jan;
38(8):1444-1453.
PMID: 38200320
Background: There are no data on pharmacokinetics, pharmacodynamics, and immunogenicity of intravitreal aflibercept in preterm infants with retinopathy of prematurity (ROP). FIREFLEYE compared aflibercept 0.4 mg/eye and laser photocoagulation in...
4.
Eissing T, Goulooze S, van den Berg P, van Noort M, Ruppert M, Snelder N, et al.
Diabetes Obes Metab
. 2023 Dec;
26(3):924-936.
PMID: 38037539
Aims: To perform dose-exposure-response analyses to determine the effects of finerenone doses. Materials And Methods: Two randomized, double-blind, placebo-controlled phase 3 trials enrolling 13 026 randomized participants with type 2...
5.
Heinig R, Eissing T
Clin Pharmacokinet
. 2023 Oct;
62(12):1673-1693.
PMID: 37875671
Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2...
6.
Gluck C, Forrest C, Goodwin Davies A, Maltenfort M, Mcdonald J, Mitsnefes M, et al.
Clin J Am Soc Nephrol
. 2023 Feb;
18(2):173-182.
PMID: 36754006
Background: The objectives of this study were to use electronic health record data from a US national multicenter pediatric network to identify a large cohort of children with CKD, evaluate...
7.
Goulooze S, Heerspink H, van Noort M, Snelder N, Brinker M, Lippert J, et al.
Clin Pharmacokinet
. 2022 May;
61(7):1013-1025.
PMID: 35508594
Background And Objective: Finerenone reduces the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes. Changes in the urine albumin-to-creatinine ratio (UACR) and estimated glomerular...
8.
Goulooze S, Snelder N, Seelmann A, Horvat-Broecker A, Brinker M, Joseph A, et al.
Clin Pharmacokinet
. 2021 Nov;
61(3):451-462.
PMID: 34786651
Background: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD...
9.
Wendl T, Frechen S, Gerisch M, Heinig R, Eissing T
CPT Pharmacometrics Syst Pharmacol
. 2021 Nov;
11(2):199-211.
PMID: 34783193
Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist that recently demonstrated its efficacy to delay chronic kidney disease (CKD) progression and reduce cardiovascular events in patients with CKD and type...
10.
van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, et al.
Clin Pharmacokinet
. 2021 Nov;
61(3):439-450.
PMID: 34773606
Background: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist that recently demonstrated efficacy in delaying chronic kidney disease progression and reducing cardiovascular events in patients with chronic kidney disease and...